FDA Approves BARACLUDE — E.R. Squibb & Sons, L.L.C.

E.R. Squibb & Sons, L.L.C. received FDA approval for Baraclude (entecavir) oral tablets in March 2005, positioning it as a potent therapeutic option for the chronic management of hepatitis B that is expected to broaden Brewer's market share in the antiviral segment.